Novartis and Pfizer are among the companies best positioned to take advantage of future biosimilars disruption in the pharmaceuticals industry, our analysis shows.
The assessment comes from GlobalData’s Thematic Research ecosystem, which ranks companies on a scale of 1–5 based on their likelihood to tackle challenges like biosimilars and emerge as long-term winners of the pharmaceuticals sector. Yesterday (19 January), using the same Thematic Research ecosystem, Clinical Trials Arena revealed the top pharma companies best equipped with artificial intelligence.
According to our analysis, Novartis, Pfizer, Catalent, Amgen, Biogen, Patheon, Shanghai Henlius Biotech, Viatris, Celltrion, and Samsung Bioepis are the companies best positioned to benefit from investments in biosimilars, all of them recording scores of 5 out of 5 in GlobalData’s drug development Thematic Scorecard.
Novartis, for example, has advertised for 406 new biosimilars jobs from January 2021 to December 2021 and mentioned biosimilars in company filings 119 times.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Pfizer indicated good levels of AI investment, with the company looking for 101 new biosimilars jobs since January 2021, completing one deal and mentioning biosimilars in filings 80 times.
The table below shows how GlobalData analysts scored the biggest companies in the pharmaceuticals industry on their biosimilars performance, as well as the number of new biosimilars jobs, deals, patents, and mentions in company reports since January 2021.